Biology-driven therapy advances in high-grade serous ovarian cancer
Journal of Clinical Investigation · 02.01.2024 · 134 (1)
DOI: 10.1172/jci174013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.01.2024. Verfasst von Yinu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology and. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, BLRD VA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology and.
- Driskill Graduate Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA.
- Jesse Brown Veteran Affairs Medical Center, Chicago, Illinois, USA.
Förderung
- NCI NIH HHS
- BLRD VA
Zitieren
APA
Wang, Y., Duval, A. J., Adli, M., & Matei, D. (2024). Biology-driven therapy advances in high-grade serous ovarian cancer. Journal of Clinical Investigation, 134(1). https://doi.org/10.1172/jci174013
Vancouver
Wang Y, Duval AJ, Adli M, Matei D. Biology-driven therapy advances in high-grade serous ovarian cancer. Journal of Clinical Investigation. 2024;134(1). doi:10.1172/jci174013
BibTeX
@article{Wang2024,
author = {Wang, Yinu and Duval, Alexander James and Adli, Mazhar and Matei, Daniela},
title = {Biology-driven therapy advances in high-grade serous ovarian cancer},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {1},
doi = {10.1172/jci174013}
}
EUVIMED